Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

TCD researchers chart chemical space in the search for new breast cancer treatments

27.11.2006
Centre for Synthesis and Chemical Biology researcher Dr Mary Meegan from the School of Pharmacy and Pharmaceutical Sciences in Trinity College Dublin with collaborators Drs Andrew Knox and David Lloyd have used computational methods to identify new leads for treating breast cancer. When tested against estrogen receptor (ER) positive cancer cell lines, 12 of the compounds performed up to 100 times better than Tamoxifen.

Estrogen and the estrogen receptor (ER)

"Estrogen works by locking into the ER, causing a change to the shape of the receptor," explains Dr Meegan. "This structural change enables the estrogen-receptor complex to bind to coactivator proteins and initiate a cascade of downstream effects resulting in cell proliferation."

Estrogen promotes cell proliferation in the breast and uterus but in breast cells with DNA mutations this process can increase the risk of developing breast cancer. This increased risk was already shown in studies involving the administration of estrogen to reduce cholesterol and maintain bone density in hormone replacement therapy (HRT).

... more about:
»Cancer »Estrogen »Meegan »Tamoxifen »antiestrogen »receptor

Tamoxifen and Raloxifene

Two of the current Selective Estrogen Receptor Modulator (SERM) drugs, Tamoxifen and Raloxifene, are antiestrogens and are used for treating breast cancer and osteoporosis respectively.

Tamoxifen mimics estrogen by preventing its binding to estrogen receptors in breast cells, but it can activate estrogen receptors in the uterus and long-term use is associated with a small increase in the risk of uterine cancer. However, it remains one of the endocrine drugs of choice for the treatment of breast cancer. Raloxifene in contrast reduces the risk of endometrial cancer and is currently used to treat osteoporosis.

Both drugs have benefits and limitations and a clinical trial called the Study of Tamoxifen and Raloxifene (STAR), due to finish this year, aims to evaluate their ability to prevent breast cancer in women who are at high risk of developing the disease.

"There is a requirement for new antiestrogen molecules that have improved specificity and toxicology profiles. We are working to identify molecules that are selective at the estrogen receptors in breast cells but which don't have a proliferative effect in other tissues," continues Dr Meegan.

Discovering new leads using structure-based drug design

Dr Meegan's group takes a practical approach to discovering potential leads for drugs. The estrogen receptor holds the key because its crystal structure and how it binds to antiestrogens is well documented. Using computational methods researchers can screen potential leads by studying their 3D conformations and binding properties.

"We group molecules with specific cancer activity together and analyse them in chemical space," continues Dr Meegan. "As part of his PhD thesis Dr Andrew Knox devised a scoring system to rate molecular fit in the estrogen receptor so we can accurately predict new leads."

Dr Knox screened thousands of molecules from drug databases using his own screening methods. He was able to narrow the search by devising a ranked hitlist where molecules with the highest score were identified for further exploration and biochemical testing. The next step in the drug discovery process was to set up a synthetic programme to explore the structure of the molecules and to design and synthesise analogues for further testing.

Dr Meegan's research group is working to develop efficient synthetic routes to the various series of compound structures identified by Dr Knox. They have tested them against ER positive, ER negative and uterine cancer lines to confirm that their action is mediated through the ER.

"The results so far have been very encouraging in that a number of the compounds identified perform better than Tamoxifen as antiestrogens and are showing no adverse effect in uterine cells. We are currently working to optimize the selective binding properties of these antiestrogenic compounds and to elucidate the mechanism of antihormonal resistance," concludes Dr Meegan.

Orla Donoghue | alfa
Further information:
http://www.ucd.ie/cscb/

Further reports about: Cancer Estrogen Meegan Tamoxifen antiestrogen receptor

More articles from Life Sciences:

nachricht Seeing on the Quick: New Insights into Active Vision in the Brain
15.08.2018 | Eberhard Karls Universität Tübingen

nachricht New Approach to Treating Chronic Itch
15.08.2018 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Unraveling the nature of 'whistlers' from space in the lab

15.08.2018 | Physics and Astronomy

Diving robots find Antarctic winter seas exhale surprising amounts of carbon dioxide

15.08.2018 | Earth Sciences

Early opaque universe linked to galaxy scarcity

15.08.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>